litlas
ログインアカウント作成

Marcin Kowanetz

2002–2024 年に発表

54
論文数
28,710
被引用数
48
h 指数
51
i10 指数

被引用数

Marcin Kowanetz の年別被引用数1995 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 2 件2003 年: 被引用 19 件2004 年: 被引用 26 件2005 年: 被引用 38 件2006 年: 被引用 58 件2007 年: 被引用 62 件2008 年: 被引用 48 件2009 年: 被引用 79 件2010 年: 被引用 68 件2011 年: 被引用 90 件2012 年: 被引用 74 件2013 年: 被引用 89 件2014 年: 被引用 150 件2015 年: 被引用 282 件2016 年: 被引用 424 件2017 年: 被引用 508 件2018 年: 被引用 641 件2019 年: 被引用 1,915 件2020 年: 被引用 2,285 件2021 年: 被引用 2,011 件2022 年: 被引用 1,431 件2023 年: 被引用 952 件2024 年: 被引用 1,195 件2025 年: 被引用 506 件2026 年: 被引用 10 件1996〜1999 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,630 件、この内訳の 23.5%中国: 引用元論文 2,766 件、この内訳の 17.9%日本: 引用元論文 824 件、この内訳の 5.4%イタリア: 引用元論文 805 件、この内訳の 5.2%フランス: 引用元論文 748 件、この内訳の 4.9%イギリス: 引用元論文 681 件、この内訳の 4.4%ドイツ: 引用元論文 680 件、この内訳の 4.4%スペイン: 引用元論文 507 件、この内訳の 3.3%韓国: 引用元論文 407 件、この内訳の 2.6%スイス: 引用元論文 388 件、この内訳の 2.5%カナダ: 引用元論文 387 件、この内訳の 2.5%オーストラリア: 引用元論文 386 件、この内訳の 2.5%
0%23.5%その他 20.9%

機関

分野

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology16.2%
  • Immunology and Microbiology9%
  • Engineering1%
  • Neuroscience0.6%
  • Materials Science0.3%
  • その他1%

トピック

  • Cancer Immunotherapy and Biomarkers20.5%
  • Lung Cancer Treatments and Mutations6.8%
  • Immunotherapy and Immune Responses6.1%
  • Lung Cancer Research Studies4.3%
  • CAR-T cell therapy research3.8%
  • Immune cells in cancer3.4%
  • その他55.1%

共著者

全論文

検索で開く
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 被引用: 3,753

  2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    著者: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 被引用: 5,302

  3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    著者: Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara - The Lancet 2016 被引用: 4,780

  4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    著者: Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo - The Lancet Oncology 2019 被引用: 1,681

  5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

    著者: Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer - The Lancet 2016 被引用: 2,803

  6. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    著者: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 被引用: 939

  7. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

    著者: Maud Mayoux, Andreas Roller, Vesna Pulko, Stefano Sammicheli, Stanford Chen, Eva Sum, Christian Jöst, Marieke F. Fransen, Regula B. Buser, Marcin Kowanetz, Karolin Rommel, Ines Matos, Sara Colombetti, Anton Belousov, Vaios Karanikas, Ferry Ossendorp, Priti S. Hegde, Daniel S. Chen, Pablo Umaña, Mario Perro, Christian Klein, Wei Xu - Science Translational Medicine 2020 被引用: 380

  8. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    著者: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 被引用: 1,195

  9. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

    著者: Shelley E. Ackerman, Cecelia I. Pearson, Joshua D. Gregorio, Joseph C. González, Justin A. Kenkel, Felix J. Hartmann, Angela Luo, Po Y. Ho, Heidi Leblanc, Lisa K. Blum, Samuel C. Kimmey, Andrew Luo, Murray L. Nguyen, Jason C. Paik, Lauren Y. Sheu, Benjamin Ackerman, Arthur Lee, Hai Li, Jennifer Melrose, Richard Laura, Vishnu C. Ramani, Karla A. Henning, David Y. Jackson, Brian S. Safina, Grant Yonehiro, Bruce H. Devens, Yaron Carmi, Steven J. Chapin, Sean C. Bendall, Marcin Kowanetz, David Dornan, Edgar G. Engleman, Michael N. Alonso - Nature Cancer 2020 被引用: 203

  10. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

    著者: Marcin Kowanetz, Xiumin Wu, John Lee, Martha Tan, Thijs J. Hagenbeek, Xueping Qu, Lanlan Yu, Jed Ross, Nina Korsisaari, Tim C. Cao, Hani Bou-Reslan, Dara Kallop, Robby M. Weimer, Mary J. C. Ludlam, Joshua S. Kaminker, Zora Modrušan, Nicholas van Bruggen, Franklin Peale, Richard A.D. Carano, Y. Gloria Meng, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 被引用: 665

  11. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

    著者: Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patrícia de Almeida, Edward E. Kadel, Shravan Madireddi, Amelia Au‐Yeung, Chikara Takahashi, Ying‐Jiun Chen, Zora Modrušan, Jacqueline McBride, Rhea Nersesian, Ehab A. ElGabry, Mark D. Robida, Jeffrey Hung, Marcin Kowanetz, Wei Zou, Mark L. McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane L. Grogan, William O’Gorman - Journal for ImmunoTherapy of Cancer 2021 被引用: 147

  12. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

    著者: Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip - Journal of Clinical Oncology 2017 被引用: 419

  13. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

    著者: Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis, Manuel Cobo, Dariusz M. Kowalski, Filippo de Marinis, Mayank Gandhi, Bradford J. Danner, Christina Matheny, Marcin Kowanetz, Pei He, Federico Felizzi, Hina Patel, Alan Sandler, Marcus Ballinger, Fabrice Barlési - Journal of Thoracic Oncology 2018 被引用: 261

  14. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    著者: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 被引用: 239

  15. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

    著者: Marius Ilié, Edith Szafer‐Glusman, Véronique Hofman, Emmanuel Chamorey, Salomé Lalvée, Éric Selva, Sylvie Leroy, Charles‐Hugo Marquette, Marcin Kowanetz, P. Hedge, Elizabeth A. Punnoose, Paul Hofman - Annals of Oncology 2017 被引用: 202

  16. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

    著者: Michael Fehlings, Suchit Jhunjhunwala, Marcin Kowanetz, William O’Gorman, Priti S. Hegde, Hermi Sumatoh, Boon Heng Lee, Alessandra Nardin, Étienne Becht, Susan Flynn, Marcus Ballinger, Evan W. Newell, Mahesh Yadav - Journal for ImmunoTherapy of Cancer 2019 被引用: 86

  17. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

    著者: Farbod Shojaei, Xiumin Wu, Xueping Qu, Marcin Kowanetz, Lanlan Yu, Martha Tan, Y. Gloria Meng, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 被引用: 469

  18. Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma

    著者: Benjamin Solomon, Richard J. Young, Mathias Bressel, Damien Urban, Shona Hendry, Alesha A. Thai, Christopher Angel, Afaf Haddad, Marcin Kowanetz, Tsien Fua, June Corry, Stephen B. Fox, Danny Rischin - Cancer Immunology Research 2018 被引用: 127

  19. TGF-β and the Smad Signaling Pathway Support Transcriptomic Reprogramming during Epithelial-Mesenchymal Cell Transition

    著者: Ulrich Valcourt, Marcin Kowanetz, Hideki Niimi, Carl‐Henrik Heldin, Aristidis Moustakas - Molecular Biology of the Cell 2005 被引用: 589

  20. Stable Expression of Angiopoietin-1 and Other Markers by Cultured Pericytes: Phenotypic Similarities to a Subpopulation of Cells in Maturing Vessels During Later Stages of Angiogenesis In Vivo

    著者: Christian Sundberg, Marcin Kowanetz, Lawrence F. Brown, Michael Detmar, Harold F. Dvorak - Laboratory Investigation 2002 被引用: 251

  21. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

    著者: Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz, Jennifer Boone, Ina Menzl, Jean‐Marie Bruey, Gregg Fine, Sanjeev Mariathasan, Ian McCaffery, Simonetta Mocci, Sandra Rost, Dustin Smith, Eslie Dennis, Szu‐Yu Tang, Bita Damadzadeh, Espen J. Walker, Priti S. Hegde, J. Andrew Williams, Hartmut Koeppen, Zachary Boyd - Applied immunohistochemistry & molecular morphology 2018 被引用: 189

  22. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

    著者: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 被引用: 172

  23. Immune profiles in primary squamous cell carcinoma of the head and neck

    著者: Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, Riyue Bao, Michael Korzinkin, Ivan V. Ozerov, Alex Zhavoronkov, David Sidransky, Atul Bedi, Mohammad Obaidul Hoque, Hartmut Koeppen, Michaela K. Keck, Arun Khattri, Nyall R. London, Nikita Kotlov, Aiman Fatima, Theodore Vougiouklakis, Yusuke Nakamura, Mark W. Lingen, Nishant Agrawal, Peter A. Savage, Stephen J. Kron, Justin Kline, Marcin Kowanetz, Tanguy Y. Seiwert - Oral Oncology 2019 被引用: 73

  24. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment

    著者: Vernon T. Phan, Xiumin Wu, Jason Cheng, Rebecca X. Sheng, Alicia S. Chung, Guanglei Zhuang, Christopher Tran, Qinghua Song, Marcin Kowanetz, Amy Sambrone, Martha Tan, Y. Gloria Meng, Erica L. Jackson, Franklin Peale, Melissa R. Junttila, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 被引用: 115